Literature DB >> 14295319

CLINICAL TRIAL OF EPSILON-AMINOCAPROIC ACID IN SEVERE HAEMOPHILIA.

A M GORDON, G P MCNICOL, A H DUBBER, G A MCDONALD, A S DOUGLAS.   

Abstract

Entities:  

Keywords:  AMINOCAPROIC ACID; BLOOD PROTEIN ELECTROPHORESIS; CLINICAL RESEARCH; DRUG THERAPY; ENZYME INHIBITORS; FACTOR VIII; FIBRINOLYSIN; HEMOPHILIA; PLACEBOS; PLASMINOGEN; STATISTICS; STREPTODORNASE AND STREPTOKINASE; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1965        PMID： 14295319      PMCID： PMC2167050          DOI： 10.1136/bmj.1.5451.1632

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  22 in total

1.  SOME PROPERTIES OF THE ANTIFIBRINOLYTICALLY ACTIVE ISOMER OF AMINO-METHYLCYCLOHEXANE CARBOXYLIC ACID.

Authors:  A H DUBBER; G P MCNICOL; A S DOUGLAS; B MELANDER
Journal:  Lancet       Date:  1964-12-19       Impact factor: 79.321

2.  Fibrinolytic mechanisms and the development of thrombolytic therapy.

Authors:  A P FLETCHER; N ALKJAERSIG; S SHERRY
Journal:  Am J Med       Date:  1962-11       Impact factor: 4.965

3.  In-vitro and in-vivo studies of a preparation of urokinase.

Authors:  G P MCNICOL; S B GALE; A S DOUGLAS
Journal:  Br Med J       Date:  1963-04-06

4.  Problems in hemostasis during openheart surgery. III. Epsilon amino caproic acid as an inhibitor of plasminogen activator activity.

Authors:  H GANS; W KRIVIT
Journal:  Ann Surg       Date:  1962-02       Impact factor: 12.969

5.  xi-Aminocaproic acid: an inhibitor of plasminogen activation.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Biol Chem       Date:  1959-04       Impact factor: 5.157

6.  Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by 6-aminocaproic acid.

Authors:  F B ABLONDI; J J HAGAN; M PHILIPS; E C DE RENZO
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

7.  The biological significance of fibrinolysis.

Authors:  T ASTRUP
Journal:  Lancet       Date:  1956-09-15       Impact factor: 79.321

8.  A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia.

Authors:  A R RAUSEN; A CRUCHAUD; C W McMILLAN; D GITLIN
Journal:  Blood       Date:  1961-12       Impact factor: 22.113

9.  Partial purification and properties of a proteolytic enzyme of human serum.

Authors:  L F REMMERT; P P COHEN
Journal:  J Biol Chem       Date:  1949-11       Impact factor: 5.157

10.  Effect of 6-amino-n-caproic acid (6-ACA) on fibrinolysis and bleeding conditions in prostatic disease.

Authors:  L ANDERSSON; I M NILSSON
Journal:  Acta Chir Scand       Date:  1961-05
View more
  6 in total

Review 1.  Basis of antifibrinolytic therapy.

Authors:  C R Prentice
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

2.  Hemolytic-uremic syndrome.

Authors: 
Journal:  Indian J Pediatr       Date:  1967-07       Impact factor: 1.967

Review 3.  Inhibitors of fibrinolysis in the treatment of haemophilia.

Authors:  C R Rizza
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

4.  Epsilon aminocaproic acid.

Authors: 
Journal:  Br Med J       Date:  1967-12-23

5.  Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.

Authors:  Karin Pm van Galen; Eveline T Engelen; Evelien P Mauser-Bunschoten; Robert Jj van Es; Roger Eg Schutgens
Journal:  Cochrane Database Syst Rev       Date:  2019-04-19

6.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.